Eve Health Group Limited has released a press release.
Omni Innovation Market Update
Filed with ASX ·
6ix hasn’t read this filing yet.
EVE Health Group Limited on 6ix
Earlier from EVE Health
- Omni Innovation secures UK Distribution Deal
- Placement to Chinese Pharmaceutical and Investment Group
- New Study- GlucoControl Improves Long-Term Glycaemic Control
- Omniblend Innovation Enters into US Representation Deal
- GlucoControl Momentum
Later from EVE Health
- Notification of Rights Issue Shortfall
- $1.6m Placement for Omni Innovation Investment
- Sales Results Exceed Expectations for Faulding GlucoControl
- Omni Innovation - US Patent Notice of Allowance Received
- Southern Cross University Collaboration with Medic Honey
Follow EVE Health into a list and get an email when it puts out news.
Follow EVE Health